[
  {
    "ts": null,
    "headline": "Aldeyra Therapeutics CEO Highlights Reproxalap Ahead of March 16 FDA Decision at Oppenheimer Conference",
    "summary": "Aldeyra Therapeutics (NASDAQ:ALDX) CEO Todd Brady provided an update on the company’s late-stage ophthalmology programs and broader pipeline during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, with much of the discussion centered on the pending FDA decision for r",
    "url": "https://finnhub.io/api/news?id=00dd2fafc0c128fdb9f1712deb19a04ee2bc47637c91b9ce00e92f40f17f0483",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772051385,
      "headline": "Aldeyra Therapeutics CEO Highlights Reproxalap Ahead of March 16 FDA Decision at Oppenheimer Conference",
      "id": 139224782,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Aldeyra Therapeutics (NASDAQ:ALDX) CEO Todd Brady provided an update on the company’s late-stage ophthalmology programs and broader pipeline during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, with much of the discussion centered on the pending FDA decision for r",
      "url": "https://finnhub.io/api/news?id=00dd2fafc0c128fdb9f1712deb19a04ee2bc47637c91b9ce00e92f40f17f0483"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Initiates Coverage of AbbVie (ABBV) with Outperform Recommendation",
    "summary": "RBC Capital Initiates Coverage of AbbVie (ABBV) with Outperform Recommendation",
    "url": "https://finnhub.io/api/news?id=4f21c71a813de7e99803fe6f0693108f56e61a16e6873ec2c6ad7b3549f82105",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772049796,
      "headline": "RBC Capital Initiates Coverage of AbbVie (ABBV) with Outperform Recommendation",
      "id": 139224412,
      "image": "",
      "related": "ABBV",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4f21c71a813de7e99803fe6f0693108f56e61a16e6873ec2c6ad7b3549f82105"
    }
  },
  {
    "ts": null,
    "headline": "Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie",
    "summary": "Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.",
    "url": "https://finnhub.io/api/news?id=fd179c9bbe20abdd9972864ad70fb56fd3bd3c1f562aeee5619e9286e4076039",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772031440,
      "headline": "Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie",
      "id": 139210537,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.",
      "url": "https://finnhub.io/api/news?id=fd179c9bbe20abdd9972864ad70fb56fd3bd3c1f562aeee5619e9286e4076039"
    }
  },
  {
    "ts": null,
    "headline": "Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More",
    "summary": "Pre-Market Stock Futures: Futures are trading higher this morning, but what a difference a day makes after a “Meltdown Monday.” Stocks rallied on Tuesday, and all major indices closed higher. While not recouping all of the losses from Monday, a strong bounce-back was a welcome sight for investors. A combination of a rebound in technology ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More",
    "url": "https://finnhub.io/api/news?id=6c5bc0e42222b3af06e96f91099f1353654595b3252e49495b59ae2201cfc060",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772024267,
      "headline": "Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More",
      "id": 139207793,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pre-Market Stock Futures: Futures are trading higher this morning, but what a difference a day makes after a “Meltdown Monday.” Stocks rallied on Tuesday, and all major indices closed higher. While not recouping all of the losses from Monday, a strong bounce-back was a welcome sight for investors. A combination of a rebound in technology ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More",
      "url": "https://finnhub.io/api/news?id=6c5bc0e42222b3af06e96f91099f1353654595b3252e49495b59ae2201cfc060"
    }
  },
  {
    "ts": null,
    "headline": "Oruka Therapeutics: A Potential Future Psoriasis Play",
    "summary": "Oruka Therapeutics: A Potential Future Psoriasis Play",
    "url": "https://finnhub.io/api/news?id=20fd663d56461d661f04230d74318f359bae608478fd3016a1ee3b0648a05e09",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772013790,
      "headline": "Oruka Therapeutics: A Potential Future Psoriasis Play",
      "id": 139209740,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=20fd663d56461d661f04230d74318f359bae608478fd3016a1ee3b0648a05e09"
    }
  },
  {
    "ts": null,
    "headline": "Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested",
    "summary": "Gilgamesh withdraws patent challenge against Enveric, leaving the key psilocybin patent uncontested.",
    "url": "https://finnhub.io/api/news?id=ba18aaaee5fdbbeb2a7abc96d00234ddc391585b24ff770cac0295567b0b00b4",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772010068,
      "headline": "Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested",
      "id": 139207124,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/25/Patent-Document-Folder-With-Lawyer-Work-.jpeg?width=2048&height=1536",
      "related": "ABBV",
      "source": "Benzinga",
      "summary": "Gilgamesh withdraws patent challenge against Enveric, leaving the key psilocybin patent uncontested.",
      "url": "https://finnhub.io/api/news?id=ba18aaaee5fdbbeb2a7abc96d00234ddc391585b24ff770cac0295567b0b00b4"
    }
  }
]